Relationship between the soluble F11 receptor and markers of inflammation in hemodialysis patients

Journal of Investigative Medicine

Volumn 55, Issue 3, 2007, Pages 115-119

  Salifu, Moro O ^a   Kolff, Quirine ^a   Murty, Preethi ^a   Haria, Dhiren M ^a   Zimpa, Mahamadu ^a   Shakeel, Muhammad ^a   Lee, Howon ^a   Kornecki, Elizabeth ^a   Babinska, Anna ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; F11 receptor; Hemodialysis; Interleukin 6; Junctional adhesion molecule A; Tumor necrosis factor

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; JUNCTIONAL ADHESION MOLECULE A; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IMMUNOASSAY; INFLAMMATION; MALE;

EID: 34548154197     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2007.06041     Document Type: Article

References (25)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
2. Vaziri ND, Gonzales EC, Wang J, et al. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 1994;23:828-35.
3. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006;70:26-33.
4. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-610.
5. Kirtchevsky SB, Cesari M, Phaor M. Inflammatory markers and cardiovascular health in older patients. Cardiovasc Res 2005;66:265-75.
6. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad and the ugly. Kidney Int 2005;67:1216-33.
7. Celi A, Lorenzet R, Furie B, Furie BC. Platelet-leukocyte-endothelial cell interaction on the blood vessel wall. Semin Hematol 1997;34:327-35.
8. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-84.
9. Babinska A, Kedees M, Athar H, et al. F11-receptor (F11R/JAM) mediates platelet adhesion to endothelial cells: role in inflammatory thrombosis. Thromb Haemost 2002;88:843-50.
10. Massberg S, Brand K, Gruner S. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002;196:887-96.
11. Zernecke A, Liehn EA, Fraemohs L, et al. Importance of junctional adhesion molecule-A for neointimal lesion formation and infiltration in atherosclerosis-prone mice. Arterioscler Thromb Vasc Biol 2006;26(2):e10-3.
12. Kornecki E, Walkowaik B, Naik UP, Ehrlich YH. Activation of human platelets by a stimulatory monoclonal antibody. J Biol Chem 1990;265:10042-8.
13. Sobocka M, Sobocki T, Babinska A, et al. Signaling pathways of the F11 receptor, aka JAM-1 in human platelets: F11R dimerization, phosphorylation and complex formation with integrin GPIII-a. J Recept Signal Transduct Res 2004;24:85-105.
14. Sobocki T, Sobocka MB, Ehrlich YH, et al. Genomic structure, organization and promoter analysis of the human F11R/F11 receptor/junctional adhesion molecule-1/JAM-A. Gene 2006;366:128-44.
15. Osterman G, Fraemohs L, Baltus T, et al. Involvement of JAM-A in mononuclear cell recruitment on inflamed or atherosclerotic endothelium: inhibition by soluble JAM-A. Arterioscler Thromb Vasc Biol 2005;25:729-35.
16. Sobocka B, Sobocki T, Banerjee P, et al. Cloning of the human platelet F11 receptor: a cell adhesion molecule member of the immunoglobulin superfamily involved in platelet aggregation. Blood 2000;95:2600-9.
17. Hopper NM, Karan EH, Turner AJ. Membrane protein secretases. Biochem J 1997;321:265-79.
18. Kimmel P, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998;55:236-44.
19. Casserly LF, Dember LM. Thrombosis in endstage renal disease. Semin Dial 2003;16:245-56.
20. Martinez-Estrada OM, Manzi L, Tonetti P, et al. Opposite effects of tumor necrosis factor and soluble fibronectin on junctional adhesion molecule-A in endothelial cells. Am J Physiol Lung Cell Mol Physiol 2005;288:L1081-8.
21. Ganster RW, Guo Z, Shao L, Geller DA. Differential effects of TNF-alpha and IFN-gamma on gene transcription mediated by NF-kappaB-Stat1-interactions. J Interferon Cytokine Res 2005;25:707-19.
22. Tian B, Nowak DE, Jamaluddin M, et al. Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling. J Biol Chem 2005;280:17435-48.
23. Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006;47:139-48.
24. Stenvinkel P, Lindholm B. C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 2005;23(1):72-8.
25. Yaron G, Brill A, Dasevsky O, et al. C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br J Haematol 2006;134:426-31.